Monday, March 19, 2018 10:49:55 AM
1. NO CAFFEINE: The volume of customer requests for no caffeine was significant. New Glucose Health® iced tea mixes are made with 100% decaffeinated black teas.
2. NEW HIGH BIOAVAILBILITY ZINC and MANGANESE: High bioavailability Zinc Picolinate and Manganese Citrate have been added to new Glucose Health® iced tea mixes, along with high bioavailability Chromium Picolinate from our original formula. High bioavailability trace minerals are more effective because they are more easily absorbed in the body. High bioavailability trace minerals in Picolinate or Citrate form can generally be purchased only at specialty nutrition retailers and pharmacies and often at much higher cost per serving, when compared to Glucose Health®.
3. NEW MICRO-NUTRIENTS: A targeted micro-nutrient mix of “B” vitamins, B6, B12 and Biotin (B7), has been added to new Glucose Health® iced tea mixes. All three vitamins are important for the unique nutritional needs of persons with pre-diabetes and Type-2 diabetes.
4. NEW BANABA LEAF: Banaba Leaf is the single most compelling alternative or traditional remedy for diabetes. For thousands of years in India, Banaba Leaf has been used in Ayurvedic medicine, one of the world’s oldest medical systems, for the management of diabetes. In 1940, the first clinical research observing the hypoglycemic and anti-hyperlipidemic properties of the naturally occurring corosolic acid in Banaba Leaf, was published.
5. FIBERSOL®-2: Glucose Health, Inc. has received valuable support from Archer Daniels Midland (ADM) in bringing our new Glucose Health® iced tea mixes to market. Fibersol®-2 is a 100% soluble fiber first developed by scientists at the Matsutani company of Japan. Clinical data, now spanning two decades, supports the beneficial impacts of Fibersol®-2, in maintaining healthy blood sugar and regular digestive health. All Fibersol®-2 used in Glucose Health® products, is manufactured by ADM in Clinton, Iowa.”
Recent GLUC News
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 12/07/2023 07:58:40 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 06/28/2023 05:23:12 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM